| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 38.1 | 34.3 | 12.9 |
| Other income | 0.6 | 0.7 | 0.1 |
| Total income | 38.7 | 35.0 | 13.0 |
| Profit before exceptional items & tax | 8.6 | 7.0 | 4.0 |
| Profit before tax | 8.6 | 7.0 | 4.0 |
| Net profit | 6.6 | 5.3 | 2.9 |
| Operating margin | 22.2% | 20.0% | 30.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +127.60% |
|---|---|
| Net profit, quarter on quarter | +24.50% |
| Revenue, year on year | +195.30% |
| Operating profit, year on year | +105.10% |
| Operating profit, quarter on quarter | +27.00% |
NSE results filing, NSE: GKSL. Figures extracted from the filing.
Gujarat Kidney and Super Speciality Ltd: key numbers
- Share price
- ₹159.98
- Market cap
- ₹1,261 Cr
- Revenue (annual)
- ₹82.01 Cr
- Net profit (annual)
- ₹15.50 Cr
- P/E (TTM)
- 79.7×Sector 53.8×
- Promoter holding
- 71.45%+0.00% QoQ
- FII holding
- 6.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Kidney and Super Speciality Ltd
All →Gujarat Kidney and Super Speciality Other Announcement
Gujarat Kidney filed Brickwork's monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation from the IPO fund-utilisation objects.
Gujarat Kidney and Super Speciality Board Meeting Date
Gujarat Kidney will hold a board meeting on 04 Nov 2026 to consider unaudited quarterly results. The trading window closes from 01 Oct 2026.
Gujarat Kidney and Super Speciality Other Announcement
This is a routine quarterly shareholding pattern disclosure for the period ended September 30, 2026, filed under SEBI Regulation 31.
Gujarat Kidney and Super Speciality Annual General Meeting
Gujarat Kidney and Super Speciality Limited held its 7th Annual General Meeting on September 28, 2026. Shareholders approved financial statements, director appointments, and various regulatory borrowing and investment limits.
Gujarat Kidney and Super Speciality Annual Report
Gujarat Kidney and Super Speciality Limited issued a corrigendum to its FY 2025-26 Annual Report. The update includes missing Secretarial Audit observations and management responses.
Gujarat Kidney and Super Speciality Annual General Meeting
Gujarat Kidney and Super Speciality Limited has issued a notice for its 7th Annual General Meeting scheduled for September 28, 2026. The meeting will address financial statements, director appointments, and related party transactions.
- Value
- ₹1.78 Cr